MedTrace Logo

Zinc Effect on Inflammation and Cardiovascular Risk in HIV

NCT05085834 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-06-12

Study results available
· View outcomes & findings →

Summary

To study the effect of short-term zinc supplementation on improving inflammation, metabolic, and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy

Conditions

Interventions

DRUG

Zinc Gluconate

Two 45 mg capsules once daily

DRUG

Placebo

Two placebo capsules once daily

Sponsors & Collaborators

  • Case Western Reserve University

    collaborator OTHER

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • University Hospitals Cleveland Medical Center

    lead OTHER

Principal Investigators

  • Grace A McComsey, MD, FIDSA · University Hospitals Cleveland Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-22
Primary Completion
2024-08-02
Completion
2024-08-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05085834 on ClinicalTrials.gov